EASD e-Learning: Bio Ketan Dhatariya

Ketan Dhatariya graduated from the University of London in 1991 and did his diabetes and endocrinology training in and around London. For two years during his training, he was also a part time General Practitioner in the evenings. He took some time out of his training to spend a year doing intensive care medicine and anaesthetics. After he finished his diabetes training in 2001, he went to do a two year research fellowship in endocrinology at Mayo Clinic in Minnesota, USA. He was appointed as a consultant in diabetes, endocrinology and general medicine at the Norfolk & Norwich University Hospital in 2004, and Honorary Professor of Medicine at the University of East Anglia in 2019.

He is a full-time NHS clinician, with no dedicated research time or funding. His predominant areas of interest are inpatient diabetes – in particular peri-operative diabetes care, the management of diabetes related emergencies, and the ‘diabetic foot’. He leads one of the largest foot clinics in the East of England.

Professor Dhatariya has several national roles in the UK. He is currently the Chair of the Association of British Clinical Diabetologists and is also the immediate past chair of the Joint British Diabetes Societies Inpatient Care Group where he led or co-authored several national guidelines on the management of various aspects of inpatient diabetes care. He is the Chair of the Examining Board for the UK Specialist Clinical Exam in Diabetes and Endocrinology. He is also a past President of the Diabetes and Endocrine section of the Royal Society of Medicine. He is the Section Co-editor for diabetes for www.endotext.org. He is an Associate Editor of Diabetic Medicine and, until 2023 was also an Associate Editor of BMJ Open Diabetes Research & Care.

Professor Dhatariya has over 210 peer reviewed publications, and has published over 25 book chapters on inpatient diabetes, peri-operative diabetes care or on the diabetic foot. He has been named as one of the world’s leading diabetes experts by www.expertscape.com

Duality of Interest: Professor Dhatariya has received speaker’s fees/honoraria or other educational activity from AstraZeneca, Menarini, Novo Nordisk, Sanofi, Boehringer-Ingelheim, Eli Lilly, Roche and Abbot.

Date: November 2024.